Ionis Pharmaceuticals Inc (NASDAQ:IONS) Shorts Reduced By 0.26%

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Corporate Logo

Ionis Pharmaceuticals Inc (NASDAQ:IONS) had a decrease of its shares shorted by 0.26%. In January was issued IONS’s total 12.89 million shares shorted by FINRA. The down change of 0.26% from 12.93 million shares was reported. Ionis Pharmaceuticals Inc (NASDAQ:IONS) has 1.21M shares average volume. It’ll cost 11 days for IONS to recover its previous position.

IONS is reaching $57.65 during the last trading session, after increased 0.79%.Currently Ionis Pharmaceuticals, Inc. is uptrending after 1.50% change in last January 9, 2018. IONS has 270,213 shares volume. IONS outperformed by 1.50% the S&P500.

Ionis Pharmaceuticals, Inc. engages in discovering and developing RNA-targeted therapeutics.The firm is worth $7.93 billion. The firm markets SPINRAZA, an antisense drug for spinal muscular atrophy in pediatric and adult patients; and Kynamro an oligonucleotide inhibitor for use in patients with homozygous familial hypercholesterolemia to reduce low density lipoprotein-cholesterol, apolipoprotein B, total cholesterol, and non-high density lipoprotein-cholesterol, and as an adjunct to lipid lowering medications and diet.Last it reported negative earnings. The Company’s drugs in Phase III development include volanesorsen for the treatment of patients with familial chylomicronemia syndrome and familial partial lipodystrophy; and IONIS-TTRRx, an antisense drug to treat all forms of transthyretin amyloidosis.

Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.